With our models, we provide evidence that oxaliplatin-resistant cancer cells have low CDX2 expression; display lower expression of both RPS and RCC genes, and are characterized by RESIST-M signature, all of which collectively correlate with clinical resistance to oxaliplatin (Supplementary Fig. S6H, I). The gene discussed is CDX2; the disease is cancer.